title: Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences.
abstract: Although graft-versus-host (GVH) disease (GVHD) is usually associated with graft versus leukemia (GVL), GVL can occur in the absence of clinical GVHD. There is evidence to suggest that GVL and GVH are mediated by different clones of T cells. The objective of this study was to identify the two types of T cells based on their receptor sequences. To this end we used irradiated nonleukemic cells from recipients as stimulator cells in a primary mixed leukocyte reaction (MLR). The activated CD4(+) donor T cells that expressed CD25 were purified by cell sorting. To prepare GVL-specific T cells, alloreactive T cells in the primary MLR were first depleted with an anti-CD25 immunotoxin. The remaining T cells had negligible alloreactivity in a secondary MLR. The allodepleted cells were then stimulated by using purified leukemia cells from the same individual as stimulator cells, and the CD25(+)-activated cells were purified by cell sorting. The GVL- and GVH-specific T cells were analyzed for their T cell receptor (TCR) clonality by using anchored RT-PCR of all the TCRbeta locus complementarity-determining region 3 (CDR3) sequences. By comparing TCRbeta CDR3 sequences from transformed bacterial colonies, we were able to demonstrate that T cells mediating GVH were different from those mediating GVL in each of the eight HLA-mismatched and one HLA-matched donor/recipient pairs. By using the appropriate TCRbeta CDR3-specific primers and probes, the GVH- and GVL-specific clones were monitored in a recipient undergoing an allogeneic stem cell transplant from her HLA-matched related donor.
authors.affiliation: Cancer Immunobiology Center and Bone Marrow Transplant Program, Department of Internal Medicine, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390, USA.
authors.forename: J
authors.initials: J
authors.lastname: Michalek
authors.forename: R H
authors.initials: RH
authors.lastname: Collins
authors.forename: H P
authors.initials: HP
authors.lastname: Durrani
authors.forename: P
authors.initials: P
authors.lastname: Vaclavkova
authors.forename: L E
authors.initials: LE
authors.lastname: Ruff
authors.forename: D C
authors.initials: DC
authors.lastname: Douek
authors.forename: E S
authors.initials: ES
authors.lastname: Vitetta
mesh_terms: D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002469:Cell Separation / Q000379:methods*; D002999:Clone Cells / Q000276:immunology*; D005434:Flow Cytometry; D006086:Graft vs Host Disease / Q000276:immunology*; D006680:HLA Antigens; D006801:Humans; D016130:Immunophenotyping / Q000379:methods; D015470:Leukemia, Myeloid, Acute / Q000276:immunology* / Q000628:therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology* / Q000628:therapy*; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes; D013997:Time Factors; D065227:Transfusion Reaction
chemical_list: D006680:HLA Antigens; D015375:Receptors, Interleukin-2